PRs this week: BLA Data on recent patients. F

Quote:

---

PRs this week:

BLA
Data on recent patients.
Financing.
Manufacturing.
Leronlimab use in UK and Italy.
Media appearances.

---

I initially viewed the $15M Convertible Preferred as potentially a sort of 'bridge' instrument, to be used in place of a larger funding agreement, if leronlimab was approved for COVID, and the government was willing to advance payment for production by Samsung (with some profit margin baked-in for CytoDyn). In other words, I viewed it as possibly being a strategic hedge that, maybe, offered the possibility of obviating the need for the formerly discussed ~$100M round.

However, I can also easily imagine the company not having the funds to fire-on-all-cylinders over the past couple of weeks, and also not having the bandwidth to close on the larger funding piece. The Q1-20 10Q shows only $1.8M in Cash and Cash Equivalents -- not much of a buffer for all that is happening behind-the-sceens.

But I think another piece of the puzzle for NP is that the terms of the larger funding piece (~$100M) probably change dramatically, and in a much more favorable direction, if the FDA approves leronlimab for COVID.

Lastly, and apropos of nothing, during the few quiet moments of the day, I have wondered how many cases of leronlimab are going to mysteriously go missing on the loading dock of Samsung Biologics in South Korea once they know that it works for COVID -- and I wondered: "How does one even begin to police that"?